Our group focuses on aging and mental health, two increasingly pressing quality of life issues. Current projects include:
• The 10X Lifespan Project: The leading anti-aging strategy, manipulating the cellular insulin/mTOR pathway, causes a 0.1X lifespan extension. In addition to quantitatively modestly extending life, it is unclear whether it is a qualitative improvement. We aim for a 10X extension of healthy living. This project is discipline agnostic, meaning we are considering theoretical, organismal, societal, and environmental approach.
• A Molecular Diagnostic for Mood: Mental health professionals lack a rigorous diagnostic tool like physicians have with glucose, cholesterol, and cell number measurements for Diabetes, Cardiovascular disease, and Cancer, respectively. We aim to change that.
• Disruptive Innovation of Blockbuster Drugs: Blockbuster drugs like the SSRIs/Lithium (Depression/Bipolar Disorder), Statins (CVD), Bisphosphonates (bone-involving diseases like Osteoporosis), and the Biguanides (Diabetes) are incumbent medicines that often have numerous reasons not to use them: they can have considerable side effects, simply not work well, and be expensive. We employ multiple technologies: CRISPR and other genetics, metabolic, computational systems approaches to identify targets for high-impact areas such as Osteoporosis and Depression/Bipolar Disorder. We have identified new targets for the Bisphosphonates and Lithium and are elucidating their biology.
Health and diseaseAging, Osteoporosis, Cardiovascular disease, Mental Health, Depression, Bipolar disease, Circadian Rhythms.
Skillsgenomics, metabolomics, genetics, biochemistry, systems biology, computational biology, biomedical engineering, bioengineering, chemical biology.
Interestssingle cell RNA seq, microfluidics, materials science, computer science, point of care diagnostics, quantified self, personalized medicine.
TherapeuticsBisphosphonates, SSRIs, Statins, Lithium.